SCHEMBL3065309

SCHEMBL3065309

O=C(NCCc1ccccc1)c1ccc(F)c(F)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.70
NPC1 O15118 12/20 0.70
HDAC2 Q92769 2/20 0.63
HDAC8 Q9BY41 2/20 0.63
HDAC6 Q9UBN7 2/20 0.63
HDAC3 O15379 1/20 0.62
HDAC4 P56524 1/20 0.62
HDAC1 Q13547 1/20 0.62
HDAC7 Q8WUI4 1/20 0.62
HDAC10 Q969S8 1/20 0.62
HDAC11 Q96DB2 1/20 0.62
HDAC9 Q9UKV0 1/20 0.62
HDAC5 Q9UQL6 1/20 0.62
MLYCD O95822 2/20 0.61
KLF5 Q13887 2/20 0.59
PKM P14618 1/20 0.56
PAX8 Q06710 1/20 0.56
HSD17B10 Q99714 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3062607 0.85 NPC1 (0.62) RAB9ANPC1HDAC2HDAC8HDAC6
SCHEMBL7702108 0.83 RAB9A (1.00) RAB9ANPC1HDAC2HDAC8HDAC6
SCHEMBL1972631 0.82 HDAC2 (0.71) RAB9ANPC1HDAC2HDAC8HDAC6
SCHEMBL992786 0.80 ESRRG (0.51) RAB9ANPC1HDAC6HDAC3HDAC1
SCHEMBL751214 0.80 HDAC2 (0.80) RAB9ANPC1HDAC2HDAC8HDAC6
SCHEMBL13202035 0.80 HDAC2 (0.65) RAB9ANPC1HDAC2HDAC8HDAC6
SCHEMBL28551980 0.80 RAB9A (0.74) RAB9ANPC1HDAC2HDAC8HDAC6
SCHEMBL6841899 0.79 HDAC2 (0.78) RAB9ANPC1HDAC2HDAC8HDAC6
SCHEMBL3513760 0.79 CES2 (0.52) HDAC3HDAC1MEN1KMT2A
SCHEMBL7282271 0.79 HDAC2 (0.78) RAB9ANPC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476297-B2 TRP-M8 receptor ligands and their use in treatments AMGEN INC. (US) 2013-07-02 US disclosed
US-8476297-B2 TRP-M8 receptor ligands and their use in treatments AMGEN INC. (US) 2013-07-02 US disclosed
US-8476297-B2 TRP-M8 receptor ligands and their use in treatments AMGEN INC. (US) 2013-07-02 US disclosed
US-20100261728-A1 TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2010-10-14 US disclosed
US-20100261728-A1 TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2010-10-14 US disclosed
US-20100261728-A1 TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2010-10-14 US disclosed
WO-2009073203-A1 TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2009-06-11 WO disclosed
WO-2009073203-A1 TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261728-A1 TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPM8, TRPV2 RAB9A 1239/4885NPC1 3217/4885HDAC2 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.